Zhiying Liu

Zhiying Liu

Auto-generated profile, based on publicly available information

Zhiying Liu

Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
Purpose: This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)–T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV–hepatocellular carcinoma after liver transplantation. Patients and Methods: In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV–TCR–T cells (mRNA–HBV–TCR–T cells) and (ii) one to three infusions of lentiviral-transduced HBV–TCR–T cells (lenti-HBV–TCR–T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficacy was evaluated using CT imaging according to RECIST v1.1 criteria. Progression-free survival (PFS) was defined as the time from the start of study treatment until objective tumor progression or death. Results: Both mRNA-electroporated and lentiviral-transduced HBV-specific TCR–T cells demonstrated a favorable safety profile, with only grade 1 to 2 treatment-related adverse events observed. In the mRNA–HBV–TCR–T cells cohort, the median PFS was 2.32 months (range, 1.87–2.77 months). The combination therapy cohort (mRNA–HBV–TCR–T cells + lenti-HBV–TCR–T cells) showed a median PFS of 7.34 months (range, 4.47–7.60 months). CT imaging indicated effective tumor control in the combination therapy group. Conclusions: This study preliminarily suggests that the combination of mRNA–HBV–TCR–T cells and lenti-HBV–TCR–T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.

29 January 2025 in JHEP Reports
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
MQMeiting Qin
Meiting Qin
YTYunhua Tang
Yunhua Tang
ZLZhiying Liu
Zhiying Liu
XHXiaoshun He
Xiaoshun He
Ischemia-free liver transplantation (IFLT) completely avoids ischemia–reperfusion injury (IRI), thus potentially reducing acute kidney injury (AKI) after liver transplantation (LT). Therefore, this study investigated whether IFLT has a protective effect against AKI after LT. In total, 862 patients who had undergone LT between 2017 to 2022 were divided into an ischemia-free liver transplantation group (IFLT group) and conventional liver transplantation group (CLT group) based on the surgical methods used. Propensity score matching (PSM) was used for post hoc randomization in the 1:1 matching between the groups. Post-transplant kidney function, graft function, and patient survival were compared between the groups. Multivariate logistic regression analysis was used to identify the risk factors of AKI after LT. Overall, 745 out of 862 patients were finally enrolled, of whom 98 underwent IFLT. PSM created 94 pairs of patients. IFLT resulted in a significant reduction in Stage-3 AKI (3.2% vs. 16.0%, p = 0.003), severe AKI (SAKI) (13.8% vs. 25.5%, p = 0.044), and renal replacement therapy (RRT) ratio (3.2% vs. 12.8%, p = 0.015) compared with the CLT group. The early allograft dysfunction (EAD) incidence of the IFLT group significantly decreased (8.5% vs. 44.7%, p <0.001). Livers from the extended criteria donation (ECD) were received in 49 patients who underwent IFLT and 46 patients who underwent CLT. Compared with the ECD-CLT group, the Stage-3 AKI and SAKI incidence in the ECD-IFLT group were both decreased (p <0.05). Multivariate logistic regression analysis further confirmed that both using IFLT and avoiding ECD were protective factors for post-transplant Stage-3 AKI. IFLT significantly reduces the incidence of post-transplant SCKI, Stage-3 AKI, and RRT. Importantly, this protective effect is also present in patients receiving ECD livers. Ischemia-free liver transplantation significantly reduces the incidence of severe acute kidney injury, Stage-3 acute kidney injury and renal replacement therapy after liver transplantation. Importantly, this protective effect is also present in patients receiving extended criteria donation livers. ChiCTR2400081755.

11 September 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
YTYunhua Tang
Yunhua Tang
JLJIahao LI
JIahao LI
MQMeiting Qin
Meiting Qin
ZLZhiying Liu
Zhiying Liu
JKJun Kang
Jun Kang
QZQiang Zhao
Qiang Zhao
Acute-on-chronic liver failure (ACLF) is a life-threatening condition with high mortality. Ischemia-free liver transplantation (IFLT), a novel clinical approach avoiding ischemia-reperfusion injury, may offer significant benefits for ACLF patients. This study included 30 ACLF patients undergoing IFLT and 97 ACLF patients undergoing conventional liver transplantation (CLT). After propensity score matching (PSM), the IFLT group comprised 28 patients, while the CLT group had 51 patients. In the PSM cohort, Kaplan-Meier analysis confirmed IFLT improved patient and graft survival for ACLF patients (log rank P=0.018 and 0.018, respectively). The IFLT group demonstrated better six-month patient survival rates (100% vs 74.5%, P=0.009) and lower post-reperfusion syndrome, shorter operative time, reduced intraoperative blood loss, less blood products use. Furthermore, ACLF patients receiving IFLT experienced fewer early allograft dysfunction, reduced intensive care unit stays, earlier extubation, faster consciousness recovery, shorter time to first flatus. Accelerated recovery of liver, circulatory, respiratory, coagulation functions were observed in the IFLT group, along with fewer acute kidney injury. Notably, ACLF patients receiving ECD livers in the IFLT group achieved better survival and clinical outcomes. Consequently, IFLT enhanced the survival rates and promoted the recovery of remote organs in ACLF patients, and improved clinical prognoses for those receiving ECD livers.

15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
Schematic diagram of the infusion dosage and schedule for HBV–TCR–T cell treatment. Lenti., lentiviral.

15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
Purpose:This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)–T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV–hepatocellular carcinoma after liver transplantation.Patients and Methods:In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV–TCR–T cells (mRNA–HBV–TCR–T cells) and (ii) one to three infusions of lentiviral-transduced HBV–TCR–T cells (lenti-HBV–TCR–T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficacy was evaluated using CT imaging according to RECIST v1.1 criteria. Progression-free survival (PFS) was defined as the time from the start of study treatment until objective tumor progression or death.Results:Both mRNA-electroporated and lentiviral-transduced HBV-specific TCR–T cells demonstrated a favorable safety profile, with only grade 1 to 2 treatment-related adverse events observed. In the mRNA–HBV–TCR–T cells cohort, the median PFS was 2.32 months (range, 1.87–2.77 months). The combination therapy cohort (mRNA–HBV–TCR–T cells + lenti-HBV–TCR–T cells) showed a median PFS of 7.34 months (range, 4.47–7.60 months). CT imaging indicated effective tumor control in the combination therapy group.Conclusions:This study preliminarily suggests that the combination of mRNA–HBV–TCR–T cells and lenti-HBV–TCR–T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.

15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
A–F, Changes in liver injury markers (ALT and AST) at different time points during HBV–TCR–T cell treatment. The shaded square area in the graph represents the reference range for each marker. The black dashed line indicates the time points of mRNA–HBV–TCR–T cell infusion, and the red dashed line indicates the time points of lenti-HBV–TCR–T cell infusion.